CalciMedica Statistics
Total Valuation
CalciMedica has a market cap or net worth of $8.26 million. The enterprise value is $1.39 million.
| Market Cap | 8.26M |
| Enterprise Value | 1.39M |
Important Dates
The last earnings date was Tuesday, November 10, 2026, before market open.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CalciMedica has 6.83 million shares outstanding. The number of shares has increased by 48.76% in one year.
| Current Share Class | 6.83M |
| Shares Outstanding | 6.83M |
| Shares Change (YoY) | +48.76% |
| Shares Change (QoQ) | +102.04% |
| Owned by Insiders (%) | 8.31% |
| Owned by Institutions (%) | 29.76% |
| Float | 3.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.97 |
| P/TBV Ratio | 1.95 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.96, with a Debt / Equity ratio of 1.63.
| Current Ratio | 4.96 |
| Quick Ratio | 4.80 |
| Debt / Equity | 1.63 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.15 |
Financial Efficiency
Return on equity (ROE) is -763.32% and return on invested capital (ROIC) is -118.67%.
| Return on Equity (ROE) | -763.32% |
| Return on Assets (ROA) | -80.28% |
| Return on Invested Capital (ROIC) | -118.67% |
| Return on Capital Employed (ROCE) | -164.16% |
| Weighted Average Cost of Capital (WACC) | 12.87% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.01M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.75% in the last 52 weeks. The beta is 1.22, so CalciMedica's price volatility has been higher than the market average.
| Beta (5Y) | 1.22 |
| 52-Week Price Change | -92.75% |
| 50-Day Moving Average | 1.54 |
| 200-Day Moving Average | 2.97 |
| Relative Strength Index (RSI) | 41.53 |
| Average Volume (20 Days) | 81,996 |
Short Selling Information
The latest short interest is 171,388, so 2.51% of the outstanding shares have been sold short.
| Short Interest | 171,388 |
| Short Previous Month | 61,641 |
| Short % of Shares Out | 2.51% |
| Short % of Float | 4.53% |
| Short Ratio (days to cover) | 2.06 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -18.76M |
| Pretax Income | -15.11M |
| Net Income | -15.11M |
| EBITDA | -18.73M |
| EBIT | -18.76M |
| Earnings Per Share (EPS) | -$3.55 |
Balance Sheet
The company has $13.77 million in cash and $6.90 million in debt, with a net cash position of $6.87 million or $1.01 per share.
| Cash & Cash Equivalents | 13.77M |
| Total Debt | 6.90M |
| Net Cash | 6.87M |
| Net Cash Per Share | $1.01 |
| Equity (Book Value) | 4.23M |
| Book Value Per Share | 0.61 |
| Working Capital | 11.35M |
Cash Flow
In the last 12 months, operating cash flow was -$19.11 million and capital expenditures -$14,000, giving a free cash flow of -$19.12 million.
| Operating Cash Flow | -19.11M |
| Capital Expenditures | -14,000 |
| Depreciation & Amortization | 26,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -19.12M |
| FCF Per Share | -$2.80 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CalciMedica does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -48.76% |
| Shareholder Yield | -48.76% |
| Earnings Yield | -293.71% |
| FCF Yield | -231.41% |
Analyst Forecast
The average price target for CalciMedica is $42.00, which is 3,371.07% higher than the current price. The consensus rating is "Buy".
| Price Target | $42.00 |
| Price Target Difference | 3,371.07% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on August 31, 2026. It was a reverse split with a ratio of 1:5.
| Last Split Date | Aug 31, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |